• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Reports Second Quarter 2023 Results

    7/28/23 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    • Net sales of $1.74 billion, decrease of 8.7%; core organic decline of 6.5%
    • Net income of ($7.3) million; Adjusted EBITDA of $343.0 million
    • Diluted GAAP EPS of ($0.01); adjusted EPS of $0.28
    • Operating cash flow of $168.2 million; free cash flow of $138.1 million
    • Adjusted net leverage of 3.9X

    RADNOR, Pa., July 28, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, education and government, advanced technologies and applied materials industries, today reported financial results for the second quarter ended June 30, 2023.

    Avantor. Setting science in motion to create a better world. (PRNewsfoto/Avantor)

    "While market trends during the quarter, especially in biopharma, were more challenging than anticipated, we leveraged the Avantor Business System to drive productivity and control costs, enabling us to deliver adjusted EBITDA margin, earnings, and free cash flow performance in line with our guidance for the quarter," said Michael Stubblefield, President and Chief Executive Officer.

    "We are confident in our platform, market position and long-term growth outlook. We continue to take action to offset current headwinds, while making strategic investments in our portfolio, global footprint and innovation platform. These efforts will enable us to meet customer needs, capitalize on growth opportunities when market trends improve and enhance shareholder value over the long term," added Stubblefield.

    Second Quarter 2023

    For the three months ended June 30, 2023, net sales were $1.74 billion, a decrease of 8.7% compared to the second quarter of 2022. Foreign currency translation had a favorable impact of 0.4% resulting in an organic sales decline of 9.1% and core organic sales (excluding COVID-19 headwinds) decline of 6.5%. Adjusted EBITDA was $343.0 million and adjusted EBITDA margin was 19.7%. Net income decreased to ($7.3) million from $187.4 million in the second quarter of 2022 and adjusted net income was $186.4 million as compared to $251.5 million in the comparable prior period.

    Our net income was negatively impacted by a non-cash impairment expense of approximately $160 million recorded in the second quarter to reflect a reduction in the fair value of our Ritter assets, driven by persistently high customer inventory in the end markets served by Ritter and an overall slowdown in the research spending environment. We remain focused on realizing the long-term growth potential of this business by introducing new products and leveraging our channel to expand Ritter's customer base.

    Diluted earnings per share on a GAAP basis was ($0.01), while adjusted EPS was $0.28.

    Operating cash flow in the quarter was $168.2 million, while free cash flow was $138.1 million.

    Adjusted net leverage was 3.9X as of June 30, 2023, and we repaid more than $400 million of total debt in the first half of 2023. We also upsized our revolver capacity in the quarter from $515 million to $975 million and extended the maturity to 2028.

    Second Quarter 2023 – Segment Results

    Management uses Adjusted EBITDA to measure and evaluate the internal operating performance of the Company's business segments. Adjusted EBITDA is also our segment reporting profitability measure under generally accepted accounting principles.

    Americas

    • Net sales were $1,025.6 million, a reported decrease of 11.3%, as compared to $1,156.6 million in the second quarter of 2022. Core organic sales decreased 8.8%.
    • Adjusted EBITDA margin decreased approximately 95 basis points to 24.1%.

    Europe

    • Net sales were $606.9 million, a reported decrease of 2.7%, as compared to $623.8 million in the second quarter of 2022. Core organic sales decreased 1.8%.
    • Adjusted EBITDA margin decreased approximately 80 basis points to 18.3%.

    AMEA

    • Net sales were $111.4 million, a reported decrease of 14.4%, as compared to $130.1 million in the second quarter of 2022. Core organic sales decreased 8.7%.
    • Adjusted EBITDA margin decreased approximately 405 basis points to 23.7%.

    Conference Call

    We will host a conference call to discuss our results today, July 28, 2023, at 8:00 a.m. Eastern Time. The live webcast and presentation as well as a replay will be available on the investor section of Avantor's website.  

    About Avantor

    Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, please visit www.avantorsciences.com.

    Use of Non-GAAP Financial Measures

    To evaluate our performance, we monitor a number of key indicators. As appropriate, we supplement our results of operations determined in accordance with U.S. generally accepted accounting principles ("GAAP") with certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measures should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measures, and such measures may not be comparable to similarly titled measures reported by other companies. Rather, these measures should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business. We strongly encourage investors to review our consolidated financial statements included in reports filed with the SEC in their entirety and not rely solely on any one, single financial measurement or communication.

    The non-GAAP financial measures used in this press release are sales growth on an organic basis, sales growth on a core organic basis, Adjusted EBITDA, adjusted net income, adjusted EPS, adjusted net leverage and free cash flow.

    • Sales growth on an organic basis eliminates from our reported net sales growth the impacts of earnings from any acquired or disposed businesses that have been owned for less than one year and changes in foreign currency exchange rates. Sales growth on a core organic basis eliminates from our organic growth the impacts of any COVID-19 related net sales. We believe that these measurements are useful as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented.
    • Adjusted EBITDA is to measure and evaluate our operating performance exclusive of interest expense, income tax expense, depreciation, amortization and certain other adjustments. We believe that this measurement is useful as a way to analyze the underlying trends in our business consistently across the periods presented.
    • Adjusted net income is our net income or loss first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) net foreign currency remeasurement gains or losses relating to financing activities, (iii) losses on extinguishment of debt, (iv) charges associated with the impairment of certain assets, (v) other costs or credits that are either isolated or cannot be expected to recur with any regularity or predictability. From this amount, we then add or subtract an assumed incremental income tax impact on the above noted pre-tax adjustments, using estimated tax rates, to arrive at Adjusted Net Income. We believe that this measurement is useful as a way to analyze the business consistently across the periods presented.
    • Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted average share count adjusted for anti-dilutive instruments. We believe that this measurement is an additional way to analyze the underlying trends in our business consistently across the periods presented.
    • Adjusted net leverage is equal to our gross debt, reduced by our cash and cash equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock-based compensation expense and including the expected run-rate effect of cost synergies and the incremental results of completed acquisitions as if those acquisitions had occurred on the first day of the trailing 12-month period). We believe that this measurement is a useful way to evaluate and measure the Company's capital allocation strategies and the underlying trends in the business.
    • Free cash flow is equal to our cash flow from operating activities, excluding acquisition-related costs paid in the period, less capital expenditures. We believe that this measurement is useful as it provides a view on the Company's ability to generate cash for use in financing or investment activities.

    Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

    Forward-Looking and Cautionary Statements

    This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "estimate," "expect," "forecast," "intend," "likely," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.

    Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.

    All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

    Investor Relations Contact

    Christina Jones

    Vice President, Investor Relations

    Avantor

    +1 805-617-5297

    [email protected]

    Media Contact

    Emily Collins

    Vice President, External Communications

    Avantor

    +1 332-239-3910

    [email protected]

     

    Avantor, Inc. and subsidiaries 

    Unaudited condensed consolidated statements of operations



    (in millions, except per share data)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2023



    2022



    2023



    2022

    Net sales

    $   1,743.9



    $   1,910.5



    $   3,524.2



    $   3,860.9

    Cost of sales

    1,153.9



    1,262.8



    2,309.4



    2,523.3

    Gross profit

    590.0



    647.7



    1,214.8



    1,337.6

    Selling, general and administrative expenses

    357.5



    352.1



    751.1



    735.0

    Impairment charges

    160.8



    —



    160.8



    —

    Operating income

    71.7



    295.6



    302.9



    602.6

    Interest expense

    (73.4)



    (63.9)



    (147.1)



    (128.7)

    Loss on extinguishment of debt

    (1.6)



    (6.1)



    (3.9)



    (7.9)

    Other income, net

    2.0



    0.7



    2.6



    2.1

    (Loss) income before income taxes

    (1.3)



    226.3



    154.5



    468.1

    Income tax expense

    (6.0)



    (38.9)



    (40.3)



    (90.3)

    Net (loss) income

    (7.3)



    187.4



    114.2



    377.8

    Accumulation of yield on preferred stock

    —



    (8.1)



    —



    (24.2)

    Net (loss) income available to common stockholders

    $        (7.3)



    $      179.3



    $      114.2



    $      353.6

















    (Loss) earnings per share:















    Basic

    $      (0.01)



    $       0.28



    $       0.17



    $       0.56

    Diluted

    $      (0.01)



    $       0.28



    $       0.17



    $       0.55

    Weighted average shares outstanding:















    Basic

    675.3



    644.2



    675.0



    627.2

    Diluted

    675.3



    680.2



    677.9



    680.8

     

    Avantor, Inc. and subsidiaries 

    Unaudited condensed consolidated balance sheets



    (in millions)

    June 30, 2023



    December 31, 2022

    Assets







    Current assets:







    Cash and cash equivalents

    $            236.4



    $            372.9

    Accounts receivable, net

    1,216.0



    1,218.4

    Inventory

    890.4



    913.5

    Other current assets

    156.3



    153.1

    Total current assets

    2,499.1



    2,657.9

    Property, plant and equipment, net

    698.2



    727.0

    Other intangible assets, net

    3,895.4



    4,133.3

    Goodwill

    5,693.9



    5,652.6

    Other assets

    276.7



    293.5

    Total assets

    $       13,063.3



    $       13,464.3

    Liabilities and stockholders' equity







    Current liabilities:







    Current portion of debt

    $            314.0



    $            364.2

    Accounts payable

    686.6



    758.2

    Employee-related liabilities

    124.3



    122.4

    Accrued interest

    49.3



    49.9

    Other current liabilities

    375.9



    364.1

    Total current liabilities

    1,550.1



    1,658.8

    Debt, net of current portion

    5,570.3



    5,923.3

    Deferred income tax liabilities

    662.8



    731.4

    Other liabilities

    268.8



    295.4

    Total liabilities

    8,052.0



    8,608.9

    Stockholders' equity:







    Common stock including paid-in capital

    3,798.6



    3,785.3

    Accumulated earnings

    1,284.6



    1,170.4

    Accumulated other comprehensive loss

    (71.9)



    (100.3)

    Total stockholders' equity

    5,011.3



    4,855.4

    Total liabilities and stockholders' equity

    $       13,063.3



    $       13,464.3

     

    Avantor, Inc. and subsidiaries 

    Unaudited condensed consolidated statements of cash flows



    (in millions)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2023



    2022



    2023



    2022

    Cash flows from operating activities:















    Net (loss) income

    $      (7.3)



    $    187.4



    $    114.2



    $    377.8

    Reconciling adjustments:















    Depreciation and amortization

    102.6



    89.7



    203.7



    204.2

    Impairment charges

    160.8



    —



    160.8



    —

    Stock-based compensation expense

    9.2



    13.0



    21.9



    23.7

    Provision for accounts receivable and

       inventory

    30.6



    12.3



    43.1



    28.2

    Deferred income tax benefit

    (38.3)



    (17.2)



    (64.7)



    (39.5)

    Amortization of deferred financing costs

    3.3



    4.1



    6.7



    8.5

    Loss on extinguishment of debt

    1.6



    6.1



    3.9



    7.9

    Foreign currency remeasurement (gain) loss

    (1.9)



    1.2



    (0.1)



    (0.6)

    Changes in assets and liabilities:















    Accounts receivable

    60.1



    39.1



    7.9



    (98.2)

    Inventory

    (8.8)



    (46.7)



    (1.7)



    (93.1)

    Accounts payable

    (75.0)



    (0.8)



    (74.4)



    72.4

    Accrued interest

    9.9



    9.1



    (0.6)



    (0.9)

    Other assets and liabilities

    (78.4)



    (69.2)



    (34.3)



    (115.4)

    Other, net

    (0.2)



    (0.6)



    1.3



    4.7

    Net cash provided by operating activities

    168.2



    227.5



    387.7



    379.7

    Cash flows from investing activities:















    Capital expenditures

    (30.1)



    (36.3)



    (58.1)



    (60.8)

    Cash paid for acquisitions, net of cash acquired

    —



    (4.9)



    —



    (20.2)

    Other

    0.7



    0.1



    1.4



    0.4

    Net cash used in investing activities

    (29.4)



    (41.1)



    (56.7)



    (80.6)

    Cash flows from financing activities:















    Debt borrowings

    —



    210.0



    —



    210.0

    Debt repayments

    (190.8)



    (412.0)



    (460.3)



    (523.9)

    Payments of debt refinancing fees and premiums

    (2.3)



    —



    (2.3)



    —

    Payments of dividends on preferred stock

    —



    (16.3)



    —



    (32.4)

    Proceeds received from exercise of stock options

    2.1



    5.9



    4.7



    11.6

    Shares repurchased to satisfy employee tax

        obligations for vested stock-based awards

    (5.2)



    (8.1)



    (13.3)



    (13.0)

    Net cash used in financing activities

    (196.2)



    (220.5)



    (471.2)



    (347.7)

    Effect of currency rate changes on cash

    (0.7)



    (13.3)



    4.1



    (17.5)

    Net change in cash, cash equivalents and restricted

       cash

    (58.1)



    (47.4)



    (136.1)



    (66.1)

    Cash, cash equivalents and restricted cash, beginning

       of period

    318.9



    308.4



    396.9



    327.1

    Cash, cash equivalents and restricted cash, end of

       period

    $    260.8



    $    261.0



    $    260.8



    $    261.0

     

    Avantor, Inc. and subsidiaries 

    Reconciliations of non-GAAP measures



    (in millions)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2023



    2022



    2023



    2022

    Net (loss) income

    $      (7.3)



    $    187.4



    $    114.2



    $    377.8

    Amortization

    78.9



    67.8



    157.3



    160.0

    Loss on extinguishment of debt

    1.6



    6.1



    3.9



    7.9

    Net foreign currency (gain) loss from financing

       activities

    (1.6)



    0.9



    (1.8)



    1.0

    Other stock-based compensation benefit

    (0.1)



    (0.4)



    —



    (1.7)

    Integration-related expenses1

    (0.6)



    3.3



    8.1



    7.2

    Purchase accounting adjustments2

    —



    13.8



    —



    9.4

    Restructuring and severance charges3

    7.2



    0.5



    11.9



    2.4

    Reserve for certain legal matters

    1.0



    —



    1.0



    —

    Impairment charges4

    160.8



    —



    160.8



    —

    Income tax benefit applicable to pretax adjustments

    (53.5)



    (27.9)



    (73.6)



    (53.7)

    Adjusted net income

    186.4



    251.5



    381.8



    510.3

    Interest expense

    73.4



    63.9



    147.1



    128.7

    Depreciation

    23.7



    21.9



    46.4



    44.2

    Income tax provision applicable to Adjusted Net income

    59.5



    66.8



    113.9



    144.0

    Adjusted EBITDA

    $    343.0



    $    404.1



    $    689.2



    $    827.2

    ━━━━━━━━━

    1.

    Represents non-recurring direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.

    2.

    Represents the non-cash reduction of contingent consideration related to the Ritter acquisition and the amortization of the purchase accounting adjustment to record inventory acquired from Masterflex at fair value.

    3.

    Reflects the incremental expenses incurred in the period related to initiatives to increase profitability and productivity. Typical costs included in this caption are employee severance, site-related exit costs, and contract termination costs.

    4.

    Related to impairment of Ritter asset group.

     

    Avantor, Inc. and subsidiaries

    Reconciliations of non-GAAP measures (continued)

     

     

    Earnings per share



    (shares in millions)

    Three months ended June 30,



    Six months ended June 30,

    2023



    2022



    2023



    2022

    Diluted (loss) earnings per share (GAAP)

    $     (0.01)



    $      0.28



    $      0.17



    $      0.55

    Dilutive impact of convertible instruments

    —



    —



    —



    —

    Fully diluted (loss) earnings per share (non-

      GAAP)

    (0.01)



    0.28



    0.17



    0.55

    Amortization

    0.12



    0.10



    0.23



    0.24

    Loss on extinguishment of debt

    —



    0.01



    0.01



    0.01

    Net foreign currency (gain) loss from financing

       activities

    —



    —



    —



    —

    Other stock-based compensation benefit

    —



    —



    —



    —

    Integration-related expenses

    —



    —



    0.01



    0.01

    Purchase accounting adjustments

    —



    0.02



    —



    0.01

    Restructuring and severance charges

    0.01



    —



    0.02



    0.01

    Reserve for certain legal matters

    —



    —



    —



    —

    Impairment charges

    0.24



    —



    0.24



    —

    Income tax benefit applicable to pretax adjustments

    (0.08)



    (0.04)



    (0.12)



    (0.08)

    Adjusted EPS (non-GAAP)

    $      0.28



    $      0.37



    $      0.56



    $      0.75

















    Weighted average shares outstanding:















    Diluted (GAAP)

    675.3



    680.2



    677.9



    680.8

    Incremental shares excluded for GAAP

    2.4



    —



    —



    —

    Share count for Adjusted EPS (non-GAAP)

    677.7



    680.2



    677.9



    680.8

     

    Avantor, Inc. and subsidiaries

    Reconciliations of non-GAAP measures (continued)

     

     

    Free cash flow



    (in millions)

    Three months ended June 30,



    Six months ended June 30,

    2023



    2022



    2023



    2022

    Net cash provided by operating activities

    $    168.2



    $    227.5



    $    387.7



    $    379.7

    Capital expenditures

    (30.1)



    (36.3)



    (58.1)



    (60.8)

    Free cash flow (non-GAAP)

    $    138.1



    $    191.2



    $    329.6



    $    318.9



    Adjusted net leverage 



    (dollars in millions)

    June 30, 2023

    Total debt, gross

    $      5,936.2

    Less cash and cash equivalents

    (236.4)



    $      5,699.8





    Trailing twelve months Adjusted EBITDA

    $      1,432.7

    Trailing twelve months ongoing stock-based compensation expense

    45.6



    $      1,478.3





    Adjusted net leverage (non-GAAP)

                  3.9 x

     

    Avantor, Inc. and subsidiaries

    Reconciliations of non-GAAP measures (continued)

     

    Net sales



    (in millions)

    June 30,



    Reconciliation of reported change to organic and core organic change

    Reported change



    Foreign currency impact



    Organic



    COVID -19



    Core organic1

    2023



    2022





    Three months ended:



























    Americas

    $  1,025.6



    $ 1,156.6



    $    (131.0)



    $     (1.2)



    $   (129.8)



    $    (28.3)



    $    (101.5)

    Europe

    606.9



    623.8



    (16.9)



    11.1



    (28.0)



    (16.8)



    (11.2)

    AMEA

    111.4



    130.1



    (18.7)



    (2.4)



    (16.3)



    (5.1)



    (11.2)

    Total

    $  1,743.9



    $ 1,910.5



    $    (166.6)



    $       7.5



    $   (174.1)



    $    (50.2)



    $    (123.9)

    Six months ended:



























    Americas

    $  2,057.6



    $ 2,300.0



    $    (242.4)



    $     (4.7)



    $   (237.7)



    $    (93.5)



    $    (144.2)

    Europe

    1,237.1



    1,304.2



    (67.1)



    (21.7)



    (45.4)



    (40.8)



    (4.6)

    AMEA

    229.5



    256.7



    (27.2)



    (8.0)



    (19.2)



    (9.3)



    (9.9)

    Total

    $  3,524.2



    $ 3,860.9



    $    (336.7)



    $    (34.4)



    $   (302.3)



    $  (143.6)



    $    (158.7)

     

    _______________

    1.

    Core organic sales growth eliminates from our organic growth the impact from the change in sales of COVID-19 related offerings from 2022 to 2023. Numbers in this column are calculated by removing the impact of COVID-19 sales from the numbers in the "Organic" column.

     

    Adjusted EBITDA



    (in millions)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2023



    2022



    2023



    2022

    Americas

    $      247.2



    $      289.8



    $      487.6



    $      584.0

    Europe

    111.2



    119.3



    232.9



    262.7

    AMEA

    26.4



    36.1



    59.9



    65.4

    Corporate

    (41.8)



    (41.1)



    (91.2)



    (84.9)

    Total

    $      343.0



    $      404.1



    $      689.2



    $      827.2

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-reports-second-quarter-2023-results-301887874.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    1/5/2026$12.00Outperform → In-line
    Evercore ISI
    12/17/2025$9.00Hold → Underperform
    Jefferies
    12/15/2025$13.00Buy → Neutral
    BofA Securities
    11/4/2025Outperform → Mkt Perform
    Raymond James
    10/30/2025$12.00Overweight → Equal Weight
    Barclays
    10/30/2025$12.00Overweight → Neutral
    Analyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    More analyst ratings

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dingemans Simon was granted 6,225 shares (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    1/12/26 5:06:55 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Dingemans Simon

    3 - Avantor, Inc. (0001722482) (Issuer)

    1/12/26 5:05:31 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Mehra Sanjeev K was granted 8,106 shares and bought $3,881,500 worth of shares (350,000 units at $11.09) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:11:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026

    RADNOR, Pa., Jan. 12, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February, 11, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avanto

    1/12/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference

    RADNOR, Pa., Jan. 5, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Emmanuel Ligner, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at approximately 8:15 a.m. Pacific Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be a

    1/5/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avantor downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Avantor from Outperform to In-line and set a new price target of $12.00

    1/5/26 8:46:17 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Jefferies with a new price target

    Jefferies downgraded Avantor from Hold to Underperform and set a new price target of $9.00

    12/17/25 8:49:45 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by BofA Securities with a new price target

    BofA Securities downgraded Avantor from Buy to Neutral and set a new price target of $13.00

    12/15/25 9:53:32 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    SEC Filings

    View All

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    12/18/25 8:17:12 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    12/4/25 4:29:41 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    11/10/25 5:11:45 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mehra Sanjeev K was granted 8,106 shares and bought $3,881,500 worth of shares (350,000 units at $11.09) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:11:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Ligner Emmanuel bought $993,125 worth of shares (87,500 units at $11.35), increasing direct ownership by 45% to 283,424 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    11/17/25 5:45:30 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $1,125,000 worth of shares (100,000 units at $11.25) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/31/25 9:46:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Sanjeev Mehra to its Board of Directors

    RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately.   Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,

    12/4/25 4:15:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

    RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit

    11/10/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026

    RADNOR, Pa., Jan. 12, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February, 11, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avanto

    1/12/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Third Quarter 2025 Results

    Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t

    10/29/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Third Quarter 2025 Earnings Call on Wednesday, October 29, 2025

    RADNOR, Pa., Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global

    10/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials